tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Morning Movers: Pharmaceuticals sink as impending tariffs seen coming
The FlyMorning Movers: Pharmaceuticals sink as impending tariffs seen coming
11d ago
BMY
BTU
Merck & Company: Buy Rating Amid Market Undervaluation and Growth Potential
PremiumRatings
Merck & Company: Buy Rating Amid Market Undervaluation and Growth Potential
12d ago
MRK
Merck assumed with a Buy at Goldman Sachs
PremiumThe Fly
Merck assumed with a Buy at Goldman Sachs
12d ago
MRK
Merck’s Promising Outlook: Buy Rating Backed by Strong Winrevair Trial Results and Market Potential
PremiumRatings
Merck’s Promising Outlook: Buy Rating Backed by Strong Winrevair Trial Results and Market Potential
18d ago
MRK
Gilead, Regeneron have most theoretical PDUFA date risk, says BofA
PremiumThe Fly
Gilead, Regeneron have most theoretical PDUFA date risk, says BofA
18d ago
MRK
GILD
Hold Rating for Merck Amid Limited Upside Potential Despite Promising Winrevair Trial Results
PremiumRatingsHold Rating for Merck Amid Limited Upside Potential Despite Promising Winrevair Trial Results
18d ago
MRK
Promising Phase 3 ZENITH Trial Results Position Sotatercept as a Potential Standard of Care for Severe PAH Despite Challenges
Premium
Ratings
Promising Phase 3 ZENITH Trial Results Position Sotatercept as a Potential Standard of Care for Severe PAH Despite Challenges
18d ago
MRK
Merck presents results from Phase 3 ZENITH trial of WINREVAIR
Premium
The Fly
Merck presents results from Phase 3 ZENITH trial of WINREVAIR
20d ago
MRK
Merck’s Subcutaneous Pembrolizumab: Strategic Developments and Market Challenges
PremiumRatings
Merck’s Subcutaneous Pembrolizumab: Strategic Developments and Market Challenges
20d ago
MRK
Unusually active option classes on open March 28th
PremiumThe Fly
Unusually active option classes on open March 28th
23d ago
APP
GME
Merck says 3475A-D77 Phase 3 trial met primary endpoints
PremiumThe Fly
Merck says 3475A-D77 Phase 3 trial met primary endpoints
24d ago
MRK
RFK Jr. plans to cut 10,000 jobs in HHS, WSJ reports
PremiumThe Fly
RFK Jr. plans to cut 10,000 jobs in HHS, WSJ reports
24d ago
AZN
BMY
Large pharma M&A deals stalling amid volatile policies, Reuters reports
PremiumThe FlyLarge pharma M&A deals stalling amid volatile policies, Reuters reports
25d ago
AZN
BMY
Merck announces EC approved Capvaxive pneumococcal vaccine
Premium
The Fly
Merck announces EC approved Capvaxive pneumococcal vaccine
25d ago
MRK
Mural Oncology halting progress of nemvaleukin trial in ovarian cancer
Premium
The Fly
Mural Oncology halting progress of nemvaleukin trial in ovarian cancer
26d ago
MRK
MURA
Merck licenses HRS-5346 in cardiovascular disease from Hengrui Pharma
PremiumThe Fly
Merck licenses HRS-5346 in cardiovascular disease from Hengrui Pharma
26d ago
MRK
Immutep announces poster presentation for the TACTI-004 Phase III trial
PremiumThe Fly
Immutep announces poster presentation for the TACTI-004 Phase III trial
1M ago
MRK
IMMP
Immunome price target lowered to $25 from $35 at Guggenheim
PremiumThe Fly
Immunome price target lowered to $25 from $35 at Guggenheim
1M ago
MRK
IMNM
FDA grants traditional approval to Keytruda for HER2-positive GEJ
PremiumThe Fly
FDA grants traditional approval to Keytruda for HER2-positive GEJ
1M ago
MRK
Trump Trade: Administration explores simplified plans for reciprocal tariffs
PremiumThe FlyTrump Trade: Administration explores simplified plans for reciprocal tariffs
1M ago
X
MS
Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination
Premium
The Fly
Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination
1M ago
BMY
MRK
Telehealth companies aggressively marketing hair-loss medicine to men, WSJ says
Premium
The Fly
Telehealth companies aggressively marketing hair-loss medicine to men, WSJ says
1M ago
MRK
OGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >